Industry Strength Score
56/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
KALA BIO INC (KALA) Stock Price & Overview
NASDAQ:KALA • US4831192020
Current stock price
0.1081 USD
0 (-1.73%)
Last:
The current stock price of KALA is 0.1081 USD. Today KALA is down by -1.73%. In the past month the price decreased by -35.52%. In the past year, price decreased by -97.2%.
KALA Key Statistics
52-Week Range0.1022 - 20.6
Current KALA stock price positioned within its 52-week range.
1-Month Range0.1022 - 0.237
Current KALA stock price positioned within its 1-month range.
- Market Cap
- 98.515M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -4.65
- Dividend Yield
- N/A
KALA Stock Performance
Today
-1.73%
1 Week
-31.75%
1 Month
-35.52%
3 Months
-80.17%
Longer-term
6 Months -86.53%
1 Year -97.20%
2 Years -98.46%
3 Years -99.33%
5 Years -99.97%
10 Years N/A
KALA Stock Chart
KALA Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to KALA. When comparing the yearly performance of all stocks, KALA is a bad performer in the overall market: 99.49% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
KALA Earnings
Next Earnings DateMay 12, 2026
Last Earnings DateApr 15, 2026
PeriodQ4 / 2025
EPS Reported-$0.67
Revenue Reported
EPS Surprise 54.38%
Revenue Surprise %
KALA Forecast & Estimates
6 analysts have analysed KALA and the average price target is 1.53 USD. This implies a price increase of 1315.36% is expected in the next year compared to the current price of 0.1081.
Analysts
Analysts43.33
Price Target1.53 (1315.36%)
EPS Next Y72.8%
Revenue Next YearN/A
KALA Financial Highlights
Over the last trailing twelve months KALA reported a non-GAAP Earnings per Share(EPS) of -4.65. The EPS increased by 57.8% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-35.84M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -143.24% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
Chartmill High Growth Momentum
EPS Q2Q%61.49%
Sales Q2Q%N/A
EPS 1Y (TTM)57.8%
Revenue 1Y (TTM)N/A
KALA Ownership
Ownership
Inst Owners0.77%
Shares911.33M
Float911.23M
Ins Owners0.01%
Short Float %0.12%
Short Ratio0.12
KALA Industry Overview
KALA operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
27%
Outperformed 27% of sub-industries
3 Month Rank
47%
Outperformed 47% of sub-industries
6 Month Rank
30%
Outperformed 30% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 4.1%
- New Lows
- 4.6%
- Average ROE
- 48.5%
- Average Profit Margin
- 20.5%
- Average Operating Margin
- 33.6%
- Average P/E
- 23.0
- Average Fwd P/E
- 18.3
- Average Debt/Equity
- 2.2
KALA Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.68 | 373.774B | ||
| AMGN | AMGEN INC | 13.75 | 186.868B | ||
| GILD | GILEAD SCIENCES INC | 14.85 | 162.401B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.8 | 108.708B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.8 | 74.75B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 27.97 | 41.295B | ||
| INSM | INSMED INC | N/A | 29.427B | ||
| NTRA | NATERA INC | N/A | 29.219B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.56B | ||
| BIIB | BIOGEN INC | 11.43 | 27.779B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.56 | 25.042B | ||
| INCY | INCYTE CORP | 10.59 | 18.96B | ||
| MRNA | MODERNA INC | N/A | 18.219B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About KALA
Company Profile
Kala Bio, Inc. is a biopharmaceutical company. The company is headquartered in Arlington, Massachusetts and currently employs 38 full-time employees. The company went IPO on 2017-07-20. The firm is engaged in the research, development, and commercialization of therapies for rare and severe diseases of the eye. The Company’s biologics-based investigational therapies utilize its proprietary mesenchymal stem cell secretome (MSC-S) platform. The Company’s product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biocfactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing, which is an underlying etiology of multiple severe ocular diseases; KPI-014 specific for inherited retinal degenerative diseases. KPI-012 is in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing. The firm is also engaged in the development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases.
Company Info
IPO: 2017-07-20
KALA BIO INC
1167 Massachusetts Avenue
Arlington MASSACHUSETTS 02472 US
CEO: Mark Iwicki
Employees: 38
Phone: 13026587581
KALA BIO INC / KALA FAQ
What does KALA do?
Kala Bio, Inc. is a biopharmaceutical company. The company is headquartered in Arlington, Massachusetts and currently employs 38 full-time employees. The company went IPO on 2017-07-20. The firm is engaged in the research, development, and commercialization of therapies for rare and severe diseases of the eye. The Company’s biologics-based investigational therapies utilize its proprietary mesenchymal stem cell secretome (MSC-S) platform. The Company’s product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biocfactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing, which is an underlying etiology of multiple severe ocular diseases; KPI-014 specific for inherited retinal degenerative diseases. KPI-012 is in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing. The firm is also engaged in the development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases.
What is the current price of KALA stock?
The current stock price of KALA is 0.1081 USD. The price decreased by -1.73% in the last trading session.
What is the dividend status of KALA BIO INC?
KALA does not pay a dividend.
How is the ChartMill rating for KALA BIO INC?
KALA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Can you provide the PE ratio for KALA stock?
KALA BIO INC (KALA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.65).
Should I buy KALA stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on KALA.
What is KALA BIO INC worth?
KALA BIO INC (KALA) has a market capitalization of 98.51M USD. This makes KALA a Micro Cap stock.